Open AccessReversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment
Author(s) -
Hasan Tahsin Gözdaş,
Oğuz Karabay
Publication year - 2015
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.150377
Subject(s) - ototoxicity , medicine , rash , audiogram , adverse effect , gastroenterology , hepatitis , chronic hepatitis , dermatology , hearing loss , pharmacology , audiology , immunology , chemotherapy , virus , cisplatin
Peginterferon alpha-2a (PEG IFN α-2a) is frequently used in chronic hepatitis B (CHB)treatment. Numerous adverse events can be noted during this therapy such as flu-like disease, rash, weight loss and depression. However, PEG IFN α-2a related ototoxicity seems to be an uncommon entity. Ototoxicity can be detected objectively by audiometry. In this paper, we present a case of CHB who developed reversible bilateral ototoxicity during PEG IFN α-2a treatment. Due to ototoxicity detected objectively by audiogram, treatment was ceased at sixth month and ototoxicity completely recovered one month after stopping the drug.